Wednesday, July 8, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Esperion Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Intelligence · Clinical Programs

Esperion Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Esperion Therapeutics.

Esperion Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ETC-1002

    Esperion Therapeutics

    Safety Evaluation of Escalating Doses

    phase 1 small molecule completed

    1 trial
  2. ETC-1002 or placebo

    Esperion Therapeutics

    Mild Dyslipidemia

    phase 1 small molecule completed

    1 trial
  3. [14C-ETC-1002]

    Esperion Therapeutics

    Hyperlipidemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Esperion Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.